肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Lancet Oncol：威罗非尼改善BRAF突变黑色素瘤患者生存

2014-03-10 MedSci原创 MedSci原创

威罗非尼改善BRAF突变黑色素瘤患者生存
关注

BRAF V600突变阳性的转移性黑色素瘤，该病是一种致命的，具有危险性的皮肤癌。BRIM-3试验旨在研究威罗非尼（vemurafenib）改善BRAF突变黑色素瘤患者生存率。BRIM-3是一项多中心Ⅲ期随机开放研究，纳入来自12个国家、104个中心、未经治疗的675例BRAFV 600突变阳性的转移性黑色素瘤患者。延长随访时间的分析结果显示，与达卡巴嗪组相比，威罗非尼(vemurafen

BRAF V600突变阳性的转移性黑色素瘤，该病是一种致命的，具有危险性的皮肤癌。BRIM-3试验旨在研究威罗非尼（vemurafenib）改善BRAF突变黑色素瘤患者生存率。

BRIM-3是一项多中心Ⅲ期随机开放研究，纳入来自12个国家、104个中心、未经治疗的675例BRAFV 600突变阳性的转移性黑色素瘤患者。

延长随访时间的分析结果显示，与达卡巴嗪组相比，威罗非尼(vemurafenib)组总生存(OS)期(13.6个月对9.7个月，P=0.0008)和无进展生存(PFS)期(6.9个月对1.6个月，P<0.0001)显著延长。威罗非尼组常见的3～4级事件为皮肤鳞癌(19%)、角化棘皮瘤(10%)、皮疹(9%)和肝功能异常(11%)，达卡巴嗪组为中性粒细胞减少(9%)。两组均有2%的患者出现5级不良事件。

研究者表示，威罗非尼能改善最常见的BRAF V600E，以及少见的BRAF V600K 突变阳性的转移性黑色素瘤。

原始出处：

McArthur GA1, Chapman PB2, Robert C3, Larkin J4, Haanen JB5, Dummer R6, Ribas A7, Hogg D8, Hamid O9, Ascierto PA10, Garbe C11, Testori A12, Maio M13, Lorigan P14, Lebbé C15, Jouary T16, Schadendorf D17, O'Day SJ18, Kirkwood JM19, Eggermont AM20, Dréno B21, Sosman JA22, Flaherty KT23, Yin M24, Caro I24, Cheng S25, Trunzer K26, Hauschild A27.Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.Lancet Oncol. 2014 Mar;15(3):323-32. doi: 10.1016/S1470-2045(14)70012-9. Epub 2014 Feb 7.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1932493, encodeId=268f193249362, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Jul 07 07:36:00 CST 2014, time=2014-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680236, encodeId=a3dd1680236c0, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sun Oct 19 15:36:00 CST 2014, time=2014-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827722, encodeId=dae6182e722ec, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 12 04:36:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864511, encodeId=c0151864511cf, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Jul 06 23:36:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354948, encodeId=4cf8135494833, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480700, encodeId=78691480e006c, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3671, encryptionId=e76836e150, topicName=BRAF突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff97667327, createdName=ms4964546379600229, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558652, encodeId=2897155865254, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564661, encodeId=f5a8156466198, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-07-07 tastas

    #患者生存#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1932493, encodeId=268f193249362, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Jul 07 07:36:00 CST 2014, time=2014-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680236, encodeId=a3dd1680236c0, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sun Oct 19 15:36:00 CST 2014, time=2014-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827722, encodeId=dae6182e722ec, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 12 04:36:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864511, encodeId=c0151864511cf, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Jul 06 23:36:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354948, encodeId=4cf8135494833, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480700, encodeId=78691480e006c, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3671, encryptionId=e76836e150, topicName=BRAF突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff97667327, createdName=ms4964546379600229, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558652, encodeId=2897155865254, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564661, encodeId=f5a8156466198, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-10-19 sunylz

    #色素#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1932493, encodeId=268f193249362, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Jul 07 07:36:00 CST 2014, time=2014-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680236, encodeId=a3dd1680236c0, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sun Oct 19 15:36:00 CST 2014, time=2014-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827722, encodeId=dae6182e722ec, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 12 04:36:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864511, encodeId=c0151864511cf, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Jul 06 23:36:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354948, encodeId=4cf8135494833, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480700, encodeId=78691480e006c, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3671, encryptionId=e76836e150, topicName=BRAF突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff97667327, createdName=ms4964546379600229, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558652, encodeId=2897155865254, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564661, encodeId=f5a8156466198, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-08-12 howi

    #Lancet#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1932493, encodeId=268f193249362, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Jul 07 07:36:00 CST 2014, time=2014-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680236, encodeId=a3dd1680236c0, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sun Oct 19 15:36:00 CST 2014, time=2014-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827722, encodeId=dae6182e722ec, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 12 04:36:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864511, encodeId=c0151864511cf, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Jul 06 23:36:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354948, encodeId=4cf8135494833, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480700, encodeId=78691480e006c, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3671, encryptionId=e76836e150, topicName=BRAF突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff97667327, createdName=ms4964546379600229, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558652, encodeId=2897155865254, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564661, encodeId=f5a8156466198, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-07-06 医者仁心

    #Oncol#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1932493, encodeId=268f193249362, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Jul 07 07:36:00 CST 2014, time=2014-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680236, encodeId=a3dd1680236c0, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sun Oct 19 15:36:00 CST 2014, time=2014-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827722, encodeId=dae6182e722ec, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 12 04:36:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864511, encodeId=c0151864511cf, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Jul 06 23:36:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354948, encodeId=4cf8135494833, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480700, encodeId=78691480e006c, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3671, encryptionId=e76836e150, topicName=BRAF突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff97667327, createdName=ms4964546379600229, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558652, encodeId=2897155865254, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564661, encodeId=f5a8156466198, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-03-12 zhaojie88

    #BRAF#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1932493, encodeId=268f193249362, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Jul 07 07:36:00 CST 2014, time=2014-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680236, encodeId=a3dd1680236c0, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sun Oct 19 15:36:00 CST 2014, time=2014-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827722, encodeId=dae6182e722ec, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 12 04:36:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864511, encodeId=c0151864511cf, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Jul 06 23:36:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354948, encodeId=4cf8135494833, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480700, encodeId=78691480e006c, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3671, encryptionId=e76836e150, topicName=BRAF突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff97667327, createdName=ms4964546379600229, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558652, encodeId=2897155865254, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564661, encodeId=f5a8156466198, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-03-12 ms4964546379600229

    #BRAF突变#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1932493, encodeId=268f193249362, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Jul 07 07:36:00 CST 2014, time=2014-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680236, encodeId=a3dd1680236c0, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sun Oct 19 15:36:00 CST 2014, time=2014-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827722, encodeId=dae6182e722ec, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 12 04:36:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864511, encodeId=c0151864511cf, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Jul 06 23:36:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354948, encodeId=4cf8135494833, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480700, encodeId=78691480e006c, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3671, encryptionId=e76836e150, topicName=BRAF突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff97667327, createdName=ms4964546379600229, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558652, encodeId=2897155865254, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564661, encodeId=f5a8156466198, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-03-12 cqlidoudou

    #黑色素#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1932493, encodeId=268f193249362, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Jul 07 07:36:00 CST 2014, time=2014-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1680236, encodeId=a3dd1680236c0, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sun Oct 19 15:36:00 CST 2014, time=2014-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827722, encodeId=dae6182e722ec, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Aug 12 04:36:00 CST 2014, time=2014-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864511, encodeId=c0151864511cf, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun Jul 06 23:36:00 CST 2014, time=2014-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1354948, encodeId=4cf8135494833, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480700, encodeId=78691480e006c, content=<a href='/topic/show?id=e76836e150' target=_blank style='color:#2F92EE;'>#BRAF突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3671, encryptionId=e76836e150, topicName=BRAF突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff97667327, createdName=ms4964546379600229, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558652, encodeId=2897155865254, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564661, encodeId=f5a8156466198, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Wed Mar 12 01:36:00 CST 2014, time=2014-03-12, status=1, ipAttribution=)]
    2014-03-12 cqlidoudou

    #黑色素#

    0